Best Practices, Strategies & Use of Novel Biological Responses for Robust Cell-Based Potency Assays (Executive Summary)

News
Article

Sponsored Content

Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Content
© 2025 MJH Life Sciences

All rights reserved.